Report Detail
Global Oligodendroglioma Treatment Market Insights, Forecast to 2025
- RnM3041370 |
- 05 March, 2019 |
- Global |
- 128 Pages |
- QYResearch |
- Pharma & Healthcare
The global Oligodendroglioma Treatment market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Oligodendroglioma Treatment market based on company, product type, end user and key regions.
This report studies the global market size of Oligodendroglioma Treatment in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Oligodendroglioma Treatment in these regions.
This research report categorizes the global Oligodendroglioma Treatment market by top players/brands, region, type and end user. This report also studies the global Oligodendroglioma Treatment market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
AngioChem Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cavion LLC
Celldex Therapeutics Inc
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Immatics Biotechnologies GmbH
Ipsen SA
Leadiant Biosciences Inc
Millennium Pharmaceuticals Inc
Northwest Biotherapeutics Inc
Novartis AG
Pfizer Inc
Tocagen Inc
Market size by Product
Alisertib
Bevacizumab
CDX-1401
Dasatinib
DCVax-L
IMA-950
Others
Market size by End User
Clinic
Hospital
ASCs
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Oligodendroglioma Treatment market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Oligodendroglioma Treatment market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Oligodendroglioma Treatment companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Oligodendroglioma Treatment submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Oligodendroglioma Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (K Pcs). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Oligodendroglioma Treatment market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Oligodendroglioma Treatment Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Oligodendroglioma Treatment Market Size Growth Rate by Product
- 1.4.2 Alisertib
- 1.4.3 Bevacizumab
- 1.4.4 CDX-1401
- 1.4.5 Dasatinib
- 1.4.6 DCVax-L
- 1.4.7 IMA-950
- 1.4.8 Others
- 1.5 Market by End User
- 1.5.1 Global Oligodendroglioma Treatment Market Size Growth Rate by End User
- 1.5.2 Clinic
- 1.5.3 Hospital
- 1.5.4 ASCs
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Oligodendroglioma Treatment Market Size
- 2.1.1 Global Oligodendroglioma Treatment Revenue 2014-2025
- 2.1.2 Global Oligodendroglioma Treatment Sales 2014-2025
- 2.2 Oligodendroglioma Treatment Growth Rate by Regions
- 2.2.1 Global Oligodendroglioma Treatment Sales by Regions
- 2.2.2 Global Oligodendroglioma Treatment Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Oligodendroglioma Treatment Sales by Manufacturers
- 3.1.1 Oligodendroglioma Treatment Sales by Manufacturers
- 3.1.2 Oligodendroglioma Treatment Sales Market Share by Manufacturers
- 3.1.3 Global Oligodendroglioma Treatment Market Concentration Ratio (CR5 and HHI)
- 3.2 Oligodendroglioma Treatment Revenue by Manufacturers
- 3.2.1 Oligodendroglioma Treatment Revenue by Manufacturers (2014-2019)
- 3.2.2 Oligodendroglioma Treatment Revenue Share by Manufacturers (2014-2019)
- 3.3 Oligodendroglioma Treatment Price by Manufacturers
- 3.4 Oligodendroglioma Treatment Manufacturing Base Distribution, Product Types
- 3.4.1 Oligodendroglioma Treatment Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Oligodendroglioma Treatment Product Type
- 3.4.3 Date of International Manufacturers Enter into Oligodendroglioma Treatment Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Oligodendroglioma Treatment Sales by Product
- 4.2 Global Oligodendroglioma Treatment Revenue by Product
- 4.3 Oligodendroglioma Treatment Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Oligodendroglioma Treatment Breakdown Data by End User
6 North America
- 6.1 North America Oligodendroglioma Treatment by Countries
- 6.1.1 North America Oligodendroglioma Treatment Sales by Countries
- 6.1.2 North America Oligodendroglioma Treatment Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Oligodendroglioma Treatment by Product
- 6.3 North America Oligodendroglioma Treatment by End User
7 Europe
- 7.1 Europe Oligodendroglioma Treatment by Countries
- 7.1.1 Europe Oligodendroglioma Treatment Sales by Countries
- 7.1.2 Europe Oligodendroglioma Treatment Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Oligodendroglioma Treatment by Product
- 7.3 Europe Oligodendroglioma Treatment by End User
8 Asia Pacific
- 8.1 Asia Pacific Oligodendroglioma Treatment by Countries
- 8.1.1 Asia Pacific Oligodendroglioma Treatment Sales by Countries
- 8.1.2 Asia Pacific Oligodendroglioma Treatment Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Oligodendroglioma Treatment by Product
- 8.3 Asia Pacific Oligodendroglioma Treatment by End User
9 Central & South America
- 9.1 Central & South America Oligodendroglioma Treatment by Countries
- 9.1.1 Central & South America Oligodendroglioma Treatment Sales by Countries
- 9.1.2 Central & South America Oligodendroglioma Treatment Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Oligodendroglioma Treatment by Product
- 9.3 Central & South America Oligodendroglioma Treatment by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Oligodendroglioma Treatment by Countries
- 10.1.1 Middle East and Africa Oligodendroglioma Treatment Sales by Countries
- 10.1.2 Middle East and Africa Oligodendroglioma Treatment Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Oligodendroglioma Treatment by Product
- 10.3 Middle East and Africa Oligodendroglioma Treatment by End User
11 Company Profiles
- 11.1 AngioChem Inc
- 11.1.1 AngioChem Inc Company Details
- 11.1.2 Company Business Overview
- 11.1.3 AngioChem Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 AngioChem Inc Oligodendroglioma Treatment Products Offered
- 11.1.5 AngioChem Inc Recent Development
- 11.2 Boehringer Ingelheim GmbH
- 11.2.1 Boehringer Ingelheim GmbH Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Boehringer Ingelheim GmbH Oligodendroglioma Treatment Products Offered
- 11.2.5 Boehringer Ingelheim GmbH Recent Development
- 11.3 Bristol-Myers Squibb Co
- 11.3.1 Bristol-Myers Squibb Co Company Details
- 11.3.2 Company Business Overview
- 11.3.3 Bristol-Myers Squibb Co Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 Bristol-Myers Squibb Co Oligodendroglioma Treatment Products Offered
- 11.3.5 Bristol-Myers Squibb Co Recent Development
- 11.4 Cavion LLC
- 11.4.1 Cavion LLC Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Cavion LLC Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Cavion LLC Oligodendroglioma Treatment Products Offered
- 11.4.5 Cavion LLC Recent Development
- 11.5 Celldex Therapeutics Inc
- 11.5.1 Celldex Therapeutics Inc Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Celldex Therapeutics Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Celldex Therapeutics Inc Oligodendroglioma Treatment Products Offered
- 11.5.5 Celldex Therapeutics Inc Recent Development
- 11.6 Eli Lilly and Co
- 11.6.1 Eli Lilly and Co Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Eli Lilly and Co Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Eli Lilly and Co Oligodendroglioma Treatment Products Offered
- 11.6.5 Eli Lilly and Co Recent Development
- 11.7 F. Hoffmann-La Roche Ltd
- 11.7.1 F. Hoffmann-La Roche Ltd Company Details
- 11.7.2 Company Business Overview
- 11.7.3 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 F. Hoffmann-La Roche Ltd Oligodendroglioma Treatment Products Offered
- 11.7.5 F. Hoffmann-La Roche Ltd Recent Development
- 11.8 Immatics Biotechnologies GmbH
- 11.8.1 Immatics Biotechnologies GmbH Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Immatics Biotechnologies GmbH Oligodendroglioma Treatment Products Offered
- 11.8.5 Immatics Biotechnologies GmbH Recent Development
- 11.9 Ipsen SA
- 11.9.1 Ipsen SA Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Ipsen SA Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Ipsen SA Oligodendroglioma Treatment Products Offered
- 11.9.5 Ipsen SA Recent Development
- 11.10 Leadiant Biosciences Inc
- 11.10.1 Leadiant Biosciences Inc Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Leadiant Biosciences Inc Oligodendroglioma Treatment Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Leadiant Biosciences Inc Oligodendroglioma Treatment Products Offered
- 11.10.5 Leadiant Biosciences Inc Recent Development
- 11.11 Millennium Pharmaceuticals Inc
- 11.12 Northwest Biotherapeutics Inc
- 11.13 Novartis AG
- 11.14 Pfizer Inc
- 11.15 Tocagen Inc
12 Future Forecast
- 12.1 Oligodendroglioma Treatment Market Forecast by Regions
- 12.1.1 Global Oligodendroglioma Treatment Sales Forecast by Regions 2019-2025
- 12.1.2 Global Oligodendroglioma Treatment Revenue Forecast by Regions 2019-2025
- 12.2 Oligodendroglioma Treatment Market Forecast by Product
- 12.2.1 Global Oligodendroglioma Treatment Sales Forecast by Product 2019-2025
- 12.2.2 Global Oligodendroglioma Treatment Revenue Forecast by Product 2019-2025
- 12.3 Oligodendroglioma Treatment Market Forecast by End User
- 12.4 North America Oligodendroglioma Treatment Forecast
- 12.5 Europe Oligodendroglioma Treatment Forecast
- 12.6 Asia Pacific Oligodendroglioma Treatment Forecast
- 12.7 Central & South America Oligodendroglioma Treatment Forecast
- 12.8 Middle East and Africa Oligodendroglioma Treatment Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Oligodendroglioma Treatment Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Oligodendroglioma Treatment . Industry analysis & Market Report on Oligodendroglioma Treatment is a syndicated market report, published as Global Oligodendroglioma Treatment Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Oligodendroglioma Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
